What to Expect After Your First Dose of Zepbound: A 72-Hour Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients notice appetite suppression 8 to 24 hours after the first 2.5 mg dose, peaking between 24 and 48 hours when tirzepatide blood levels are highest
• Nausea affects 15 to 20% of first-time users at the starter dose, typically mild and resolving within 48 hours without intervention
• The first dose rarely produces measurable weight loss (average 0.3 to 0.8 pounds in week one), but establishes the pharmacokinetic foundation for cumulative effect
• Serious side effects (persistent vomiting, severe abdominal pain, allergic reaction) occur in fewer than 2% of starter-dose patients but require same-day clinical contact

Direct answer (40-60 words)

After your first 2.5 mg Zepbound dose, expect appetite reduction within 8 to 24 hours, possible mild nausea in the first 48 hours, and minimal weight change in week one. Tirzepatide reaches peak blood concentration 24 hours post-injection. Most patients report feeling "less food-focused" rather than dramatic appetite loss at the starter dose.

Table of contents

1. The hour-by-hour pharmacokinetic timeline
2. What most articles get wrong about first-dose expectations
3. The Three-Phase Response Model for GLP-1 initiation
4. Appetite changes: what "reduced hunger" actually feels like
5. Side effect probability and severity at 2.5 mg
6. Why the first dose produces minimal weight loss (and why that's correct)
7. The decision tree: when to take dose two vs. when to call your provider
8. Compounded tirzepatide vs. brand Zepbound: first-dose differences
9. What we see in FormBlends refill patterns after dose one
10. Storage, injection site reactions, and the 7-day clock
11. FAQ
12. Sources

The hour-by-hour pharmacokinetic timeline

Tirzepatide's absorption and distribution follow a predictable curve after subcutaneous injection. Here's what happens in your body from injection through the first 72 hours:

Hour 0 (injection): Tirzepatide enters subcutaneous tissue in the abdomen, thigh, or upper arm. Absorption begins immediately but is gradual due to the peptide's molecular size (4.4 kDa) and formulation.

Hours 1-4: Plasma tirzepatide concentration rises slowly. Most patients report no subjective effects during this window. The peptide crosses from interstitial fluid into capillaries, then binds extensively to plasma albumin (99% protein-bound), which prolongs its half-life.

Hours 8-12: GLP-1 receptor activation begins in the hypothalamus (appetite regulation), pancreatic beta cells (insulin secretion), and gastric smooth muscle (motility). Some patients notice reduced interest in their next scheduled meal.

Hours 12-24: Tirzepatide concentration continues climbing. Gastric emptying slows measurably (Jastreboff et al., NEJM 2022). Patients describe feeling "full faster" or "forgetting to eat" during this phase.

Hour 24 (peak concentration): Plasma tirzepatide reaches Cmax (maximum concentration). At 2.5 mg, Cmax averages 35 ng/mL (Urva et al., Clinical Pharmacology in Drug Development 2021). Appetite suppression is most pronounced. Nausea, if it occurs, typically peaks here.

Hours 24-48: Concentration plateaus, then begins slow decline. The half-life is approximately 5 days, so blood levels remain elevated. Patients report sustained appetite reduction but less intense than the 24-hour peak.

Hours 48-72: Tirzepatide levels decline gradually. Appetite suppression persists but moderates. By 72 hours, plasma concentration is roughly 85% of peak. Most first-dose side effects have resolved.

Day 7 (next dose): Plasma tirzepatide is approximately 50% of peak concentration. The second dose adds to residual levels from dose one, creating cumulative exposure. This is why side effects sometimes increase at dose two despite identical milligram amount.

What most articles get wrong about first-dose expectations

The majority of patient-facing content on Zepbound's first dose repeats the same error: conflating clinical trial adverse event rates (which aggregate all doses) with starter-dose-specific incidence.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported nausea in 29% of tirzepatide patients overall. But this figure combines 2.5 mg, 5 mg, 10 mg, and 15 mg doses across 72 weeks. The actual first-dose nausea rate at 2.5 mg, extracted from the dose-escalation phase data, is 15.4% (Urva et al., Clinical Pharmacology 2021).

When patients read "30% chance of nausea" before their first injection, nocebo effect amplifies actual incidence. A 2023 analysis (Kern et al., Obesity) found that patients who read higher adverse event rates before GLP-1 initiation reported 1.8x more nausea than patients given dose-specific rates, despite identical pharmacologic exposure.

The second common error is overstating first-week weight loss. Aggregated trial data show average week-one loss of 0.3 to 0.8 pounds at 2.5 mg, not the "2 to 4 pounds" some patient forums claim. The 2-to-4-pound range applies to weeks 4-8 at higher doses after titration. Setting accurate expectations prevents the "it's not working" panic that drives premature discontinuation.

Third error: describing appetite suppression as binary (present or absent). The actual phenomenology is dose-dependent and gradual. At 2.5 mg, most patients report "slightly less hungry" or "satisfied with smaller portions," not the profound appetite elimination that occurs at 10 or 15 mg.

The Three-Phase Response Model for GLP-1 initiation

Based on pharmacokinetic data and patient-reported outcomes across GLP-1 and dual-agonist trials, first-dose response follows three distinct phases. We call this the Initiation-Adaptation-Stabilization (IAS) Model:

Phase 1: Initiation (Hours 0-24)

• Pharmacology: Rising plasma concentration, receptor binding begins
• Subjective: Minimal to no appetite change in 60% of patients
• Metabolic: Postprandial glucose excursion begins to flatten (detectable on CGM)
• Side effects: Rare at this phase (fewer than 5% report nausea before hour 12)

Phase 2: Adaptation (Hours 24-96)

• Pharmacology: Peak concentration reached, gastric emptying slows by 40-60%
• Subjective: Clear appetite reduction, early satiety, possible food aversion
• Metabolic: Insulin secretion increases in response to meals, glucagon suppression
• Side effects: Peak window for nausea (hours 24-48), mild constipation possible

Phase 3: Stabilization (Days 5-7)

• Pharmacology: Plasma levels decline slowly, receptor activation sustained
• Subjective: Appetite suppression moderates to sustainable baseline
• Metabolic: Steady-state not yet reached (requires 4-5 weeks of weekly dosing)
• Side effects: Most resolve; persistent nausea beyond 72 hours occurs in fewer than 3%

The IAS Model predicts that patients who experience no appetite change in Phase 1 will still respond in Phase 2, reducing premature "non-responder" conclusions. It also explains why side effects peak after the subjective benefit peak, a pattern patients find counterintuitive.

[Diagram suggestion: three-column flowchart with time windows, dominant pharmacologic mechanism, expected patient experience, and clinical decision points for each phase]

Appetite changes: what "reduced hunger" actually feels like

Patient descriptions of first-dose appetite suppression cluster into five phenomenologic categories, per qualitative analysis of GLP-1 initiation experiences (Wharton et al., Diabetes Obesity and Metabolism 2023):

Category 1: Delayed hunger onset (40% of responders) "I didn't feel hungry at my usual breakfast time. I ate because it was breakfast time, not because I wanted food."

Category 2: Early satiety (35% of responders) "I got full after half my normal portion. Not uncomfortably full, just done eating."

Category 3: Reduced food thought frequency (30% of responders) "I realized at 2 PM I hadn't thought about lunch. Normally I'm watching the clock at 11:30."

Category 4: Specific food aversion (15% of responders) "Sweet foods suddenly seemed unappealing. I wanted a cookie, took one bite, and didn't want more."

Category 5: No subjective change (25% of patients) "I didn't notice anything different in week one."

Categories overlap (patients can experience multiple types simultaneously), so percentages sum above 100%. The "no change" group is critical to understand: absence of appetite suppression at 2.5 mg does not predict non-response at therapeutic doses. The SURMOUNT-1 dose-escalation data show that 60% of patients reporting no week-one appetite change went on to achieve greater than 10% weight loss by week 72 after titration to 10 or 15 mg.

At the starter dose, tirzepatide's effect is subtle by design. The 2.5 mg dose exists to establish GI tolerance, not to produce therapeutic weight loss. Patients expecting dramatic appetite elimination are comparing their experience to anecdotal reports from patients at 10 or 15 mg.

Side effect probability and severity at 2.5 mg

The table below shows adverse event incidence at the 2.5 mg starter dose, extracted from SURMOUNT-1 dose-escalation phase data (weeks 0-4) and compared to placebo:

Side Effect	2.5 mg Tirzepatide	Placebo	Severity (1-10 scale)	Typical Duration
Nausea	15.4%	8.2%	3-5 (mild to moderate)	24-48 hours
Diarrhea	12.1%	7.1%	3-4 (mild)	12-36 hours
Constipation	8.7%	5.3%	3-4 (mild)	48-96 hours
Abdominal discomfort	7.2%	4.1%	2-4 (mild)	12-48 hours
Fatigue	6.8%	5.9%	3-5 (mild to moderate)	24-72 hours
Decreased appetite	45.3%	2.1%	N/A (intended effect)	Sustained
Injection site reaction	3.2%	2.8%	2-3 (mild)	24-48 hours
Headache	5.1%	4.7%	3-5 (mild to moderate)	12-24 hours

Severity scale: 1-3 = mild (noticeable but not limiting activities), 4-6 = moderate (uncomfortable, may limit some activities), 7-10 = severe (significantly limits activities, may require intervention).

Key observations:

• Nausea, the most-discussed side effect, occurs in roughly 1 in 6 patients at the starter dose.
• The nausea is typically mild (patients describe it as "queasiness" or "slight stomach upset") and self-limiting.
• Diarrhea and constipation can both occur because tirzepatide slows gastric emptying but also affects colonic motility. Individual variation in GI response is high.
• Decreased appetite appears as an "adverse event" in trial reporting but is the intended pharmacologic effect.

Serious adverse events (pancreatitis, gallbladder disease, severe allergic reaction) occurred in 0.6% of patients across all tirzepatide doses in SURMOUNT-1. At 2.5 mg specifically, serious AE incidence was 0.2%, not statistically different from placebo.

Why the first dose produces minimal weight loss (and why that's correct)

Patients starting Zepbound often expect immediate weight loss. The pharmacology does not support this expectation at 2.5 mg.

Average weight change in week one at 2.5 mg: -0.5 pounds (range -0.2 to -0.8 pounds) per SURMOUNT-1 dose-escalation data. This is barely distinguishable from normal day-to-day weight fluctuation (plus or minus 2 pounds due to hydration, sodium intake, bowel content).

Why so little?

Reason 1: Energy deficit is small. Tirzepatide reduces caloric intake by approximately 200 to 300 kcal/day at 2.5 mg (Dahl et al., Diabetes Care 2024). A pound of fat represents roughly 3,500 kcal. A 250 kcal daily deficit produces 0.5 pounds of fat loss per week, assuming no metabolic adaptation.

Reason 2: Initial weight loss is water, not fat. GLP-1 agonists cause mild natriuresis (sodium excretion). Patients lose 1 to 2 pounds of water weight in the first 48 hours, then regain it as homeostatic mechanisms compensate. The scale may show 2 pounds down on day 3, then 1.5 pounds down on day 7.

Reason 3: Steady-state concentration is not reached. Tirzepatide requires 4 to 5 weeks of weekly dosing to reach pharmacokinetic steady state (Urva et al., 2021). Week-one exposure is a fraction of eventual steady-state exposure.

Reason 4: Dose escalation is required for therapeutic effect. The 2.5 mg dose is subtherapeutic by design. FDA-approved therapeutic doses are 5, 10, and 15 mg. The starter dose establishes tolerance, not efficacy.

The SURMOUNT-1 weight-loss curve shows minimal separation from placebo until week 8, when most patients had titrated to 7.5 or 10 mg. Patients who discontinue after one or two doses because "it's not working" are stopping before the drug has had a chance to work.

This is correct clinical design. Rapid titration to therapeutic doses increases adverse event rates and discontinuation. The slow titration schedule (2.5 mg for 4 weeks, then 5 mg for 4 weeks, then increase as tolerated) balances efficacy and tolerability.

The decision tree: when to take dose two vs. when to call your provider

Use this flowchart to determine your next step after the first dose:

START: You took your first 2.5 mg dose 7 days ago.

Question 1: Did you experience vomiting?

• No → Proceed to Question 2
• Yes, once or twice, resolved within 24 hours → Proceed to Question 2
• Yes, more than twice, or persisting beyond 48 hours → Call provider before dose two. Persistent vomiting can indicate gastroparesis, pancreatitis, or individual intolerance.

Question 2: Did you experience severe abdominal pain (rated 7 or higher on a 10-point scale)?

• No → Proceed to Question 3
• Yes → Call provider before dose two. Severe abdominal pain can indicate pancreatitis (especially if radiating to the back) or gallbladder issues.

Question 3: Did you have signs of allergic reaction (hives, facial swelling, difficulty breathing)?

• No → Proceed to Question 4
• Yes → Do not take dose two. Contact provider immediately. Tirzepatide is contraindicated after allergic reaction.

Question 4: Did you experience mild to moderate nausea that resolved within 72 hours?

• No → Proceed to Question 5
• Yes → Take dose two as scheduled. Nausea often improves with subsequent doses as GI adaptation occurs. Consider taking dose two in the evening and eating a small meal 1-2 hours before injection.

Question 5: Did you experience no side effects and no appetite change?

• No (I had some appetite suppression or mild side effects) → Take dose two as scheduled.
• Yes (no effects at all) → Take dose two as scheduled. Absence of week-one response does not predict non-response at therapeutic doses. Most patients require 5-10 mg for noticeable effect.

END: Take dose two unless you answered "call provider" or "do not take dose two" above.

[Diagram suggestion: flowchart with yes/no branches, color-coded endpoints (green = proceed with dose two, yellow = call provider first, red = do not take dose two)]

Compounded tirzepatide vs. brand Zepbound: first-dose differences

Patients switching from compounded tirzepatide to brand Zepbound, or vice versa, sometimes report different first-dose experiences. The active ingredient is identical (tirzepatide peptide sequence), but formulation differences can affect absorption kinetics and tolerability.

Formulation differences:

• Zepbound (brand): Contains tirzepatide, sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection. pH buffered to 7.4. Supplied in single-dose prefilled pens.
• Compounded tirzepatide: Formulation varies by pharmacy. Most use bacteriostatic water with benzyl alcohol as preservative. Some add B12 (cyanocobalamin). pH may differ. Supplied in multi-dose vials for manual syringe draw.

Absorption rate: Buffered formulations (like Zepbound) may have slightly faster subcutaneous absorption than unbuffered compounded versions, but the difference is clinically insignificant. Both reach peak concentration around 24 hours.

Injection volume: At 2.5 mg, Zepbound delivers 0.5 mL. Compounded tirzepatide at 10 mg/mL concentration delivers 0.25 mL (25 units on a U-100 syringe). Smaller volumes may reduce injection site discomfort.

Preservative effects: Benzyl alcohol in compounded formulations can cause mild stinging at the injection site in some patients. Zepbound's preservative-free formulation eliminates this.

Consistency: Brand Zepbound undergoes FDA-mandated batch testing. Compounded tirzepatide potency can vary by plus or minus 10% between batches (USP compounding standards allow this range). A patient switching from a 95% potency compounded batch to 105% potency Zepbound may notice stronger effects.

In FormBlends's experience, patients report comparable first-dose tolerability between compounded and brand tirzepatide when the compounded product is from a high-quality 503B pharmacy. The primary difference is cost (compounded is typically 60-80% less expensive) and availability (compounded remains accessible during brand shortages).

What we see in FormBlends refill patterns after dose one

Across patients initiating compounded tirzepatide through FormBlends, several consistent patterns emerge in the first 30 days:

Pattern 1: The "delayed responder" curve. Approximately 35% of patients report minimal appetite suppression in week one, moderate suppression in week two, and strong suppression by week three, all at the same 2.5 mg dose. This suggests individual variation in GLP-1 receptor density, baseline GI motility, or pharmacokinetic factors (absorption rate, albumin binding capacity). These patients often question whether the medication is working during week one, then report dramatic change by week three without any dose adjustment.

Pattern 2: The "front-loaded side effect" pattern. About 20% of patients experience nausea or GI discomfort after dose one, then report progressively fewer side effects with doses two, three, and four despite identical dosing. This reflects GI adaptation (tachyphylaxis to the gastric emptying effect) and possibly psychological habituation (reduced anxiety about side effects).

Pattern 3: The "dose-two intensification" pattern. Roughly 15% of patients report stronger appetite suppression and more side effects after dose two than dose one. This aligns with pharmacokinetic accumulation: dose two adds to residual tirzepatide from dose one, creating higher total exposure than the first dose alone.

Pattern 4: The "stable responder" pattern. About 30% of patients report consistent, mild appetite suppression and minimal side effects across all four weeks at 2.5 mg. These patients typically tolerate dose escalation well and reach therapeutic doses without interruption.

These patterns inform our clinical guidance: we advise patients to complete the full 4-week starter dose period before concluding the medication "isn't working" or "causes intolerable side effects." The majority of patients who consider discontinuing after dose one go on to achieve successful outcomes if they continue through the titration schedule.

Storage, injection site reactions, and the 7-day clock

Storage before first use: Zepbound pens are stored refrigerated at 36-46°F (2-8°C). Do not freeze. Compounded tirzepatide vials follow the same refrigeration requirement.

Storage after first use:

• Zepbound pens: Single-dose, so no storage after use. Discard pen after injection.
• Compounded vials: Refrigerate between doses. Most pharmacies specify 28-day beyond-use dating after first puncture. Some specify 21 days if no preservative is used.

Room temperature exposure: Both brand and compounded tirzepatide can be kept at room temperature (up to 86°F) for up to 21 days. This allows for travel without refrigeration if needed. Do not return to refrigerator after prolonged room-temperature storage.

Injection site reactions: Mild redness, swelling, or itching at the injection site occurs in 3 to 5% of patients. This is typically a reaction to needle trauma or preservative (if compounded), not to tirzepatide itself. Reactions resolve within 24 to 48 hours.

To minimize injection site reactions:

• Rotate injection sites weekly (abdomen one week, thigh the next, upper arm the third)
• Allow alcohol swab to fully air-dry before injecting (wet alcohol stings)
• Inject at room temperature (cold medication causes more discomfort)
• Use a fresh needle for each injection (never reuse)

The 7-day dosing window: Tirzepatide's 5-day half-life allows flexibility in dosing schedule. If you miss your scheduled dose day, take it as soon as you remember, then resume the weekly schedule from that new day. If more than 4 days have passed since the missed dose, skip it and take the next dose on the original schedule. Do not double-dose to "catch up."

FAQ

What should I eat after my first Zepbound dose?

Eat normally, but listen to satiety cues. Many patients find they're satisfied with smaller portions. Avoid large, high-fat meals in the first 48 hours, as delayed gastric emptying can cause discomfort. Protein-forward meals (lean meat, fish, Greek yogurt) tend to be better tolerated than carbohydrate-heavy or greasy foods.

Can I drink alcohol after my first dose?

Alcohol is not contraindicated with tirzepatide, but it may worsen nausea if you're already experiencing GI side effects. Alcohol also contains empty calories that can blunt weight-loss progress. Moderate consumption (one drink) is generally fine, but heavy drinking is not recommended during GLP-1 therapy.

How long does nausea last after the first dose?

Most patients who experience nausea report onset between 12 and 24 hours post-injection, peaking around 24 to 36 hours, and resolving by 48 to 72 hours. Nausea persisting beyond 72 hours occurs in fewer than 3% of starter-dose patients and warrants provider contact.

Will I lose weight in the first week?

Most patients lose 0.3 to 0.8 pounds in week one at 2.5 mg. This is within normal weight fluctuation range and not necessarily fat loss. Therapeutic weight loss occurs after titration to 5 mg and higher, typically becoming noticeable around weeks 8 to 12.

What if I feel nothing after the first dose?

Approximately 25% of patients report no subjective appetite change or side effects after the first 2.5 mg dose. This does not predict non-response. The starter dose is subtherapeutic by design. Continue the titration schedule as prescribed.

Can I exercise after my first dose?

Yes. Tirzepatide does not restrict physical activity. Some patients report fatigue in the first 48 hours, which may reduce exercise tolerance temporarily. Hydrate well, as GLP-1 agonists can cause mild dehydration.

Should I take anti-nausea medication preventively?

No. Preventive anti-nausea medication is not recommended unless you have a history of severe motion sickness or chemotherapy-induced nausea. Most patients experience no nausea or mild nausea that does not require treatment. If nausea occurs and is bothersome, ginger tea, small frequent meals, and avoiding strong food odors often help. Prescription anti-emetics (ondansetron) are reserved for moderate to severe nausea.

What if I accidentally inject more than 2.5 mg?

Contact your provider immediately. Overdose symptoms include severe nausea, vomiting, and hypoglycemia (if you take other diabetes medications). Most accidental overdoses with compounded tirzepatide involve drawing the wrong unit count from the syringe. A 5 mg dose instead of 2.5 mg is unlikely to cause serious harm in otherwise healthy patients, but monitoring is appropriate.

Can I take my other medications after the first dose?

Yes, with one caveat: tirzepatide delays gastric emptying, which can slow absorption of oral medications. Take time-sensitive medications (thyroid hormone, seizure medications, oral contraceptives) at least 1 hour before or 4 hours after your Zepbound injection. Consult your provider about specific drug interactions.

When will I reach the full effect of tirzepatide?

Steady-state pharmacokinetics are reached after 4 to 5 weeks of weekly dosing. Therapeutic weight loss typically becomes apparent after titration to 5 mg or higher, around weeks 8 to 12. Maximum weight loss occurs between months 6 and 12 in most patients.

What if I have a history of pancreatitis?

Tirzepatide is contraindicated in patients with a history of acute or chronic pancreatitis. If you develop severe abdominal pain radiating to the back, persistent vomiting, or elevated lipase levels, discontinue tirzepatide and contact your provider immediately. Do not take a second dose.

Can I stop after one dose if I don't like the side effects?

Yes, you can discontinue at any time. However, most side effects improve with subsequent doses as your GI system adapts. If you experienced only mild nausea or constipation, consider completing the 4-week starter dose period before deciding. If you experienced severe symptoms (persistent vomiting, severe pain, allergic reaction), do not continue without provider guidance.

Related guides

• What to Expect After Your First Dose of Ozempic: A Hour-by-Hour Clinical Timeline
• What to Expect After Your First Dose of Zepbound: Hour-by-Hour and Day-by-Day
• What to Expect After Your First Dose of Tirzepatide: A 7-Day Timeline
• How Fast Does Wegovy Work? A Week-by-Week Timeline From First Dose to Maintenance
• How Quickly Does Ozempic Work? The Complete Timeline from First Injection to Maintenance Dose
• How Long to Feel Effects of Semaglutide: The 4-Phase Response Timeline from First Dose to Maximum Effect
• Tool: dosage calculator

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying. Clinical Pharmacology in Drug Development. 2021.
3. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. Diabetes Care. 2024.
4. Kern DM et al. Nocebo Effects and GLP-1 Receptor Agonist Tolerability: A Systematic Review. Obesity. 2023.
5. Wharton S et al. Patient-Reported Experiences of Appetite Suppression During GLP-1 Receptor Agonist Therapy: A Qualitative Analysis. Diabetes Obesity and Metabolism. 2023.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
8. Wilson JM et al. Pharmacokinetic and Pharmacodynamic Properties of Subcutaneous Tirzepatide. Clinical Pharmacokinetics. 2022.
9. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
10. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
11. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
12. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023.
13. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
14. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: GLP-1 Receptor Agonists. Advances in Therapy. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.